

Pre-close brief Q4 and Full year 2024

Gothenburg, Sweden on December 09, 2024


In line with the latest ESMA guidelines on pre-close calls, we will no longer have such. The purpose of this pre-close brief is to provide a summary of links and information as a support to the public ahead of the next quarterly report.

Financial target 2024-2028

- **>12% adjusted EPS CAGR:** Communicated on slide 11 in the Capital Markets Update on May 15, 2024.

Outlook

- **Short-term:**
 - **Net Sales:** Our latest outlook on net sales for 2024 was provided on page 1 in the Q3 2024 report released on October 18, 2024.
 - **EBITA margin:** Our latest outlook on EBITA margin for 2024-2025 was provided on slide 14 and in the call of the Capital Markets Update on May 15, 2024. Please see call transcript.
- **2024-2028:**
 - **Net Sales:** Our latest outlook on net sales for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.
 - **EBITA margin:** Our latest outlook on EBITA margin for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.



Reports and Transcripts from earnings calls and Capital Markets Update

- Capital Markets Update (May 15, 2024)
 - [Presentation / Transcript](#)
- Q3 2024 (October 18, 2024)
 - [Report / Transcript](#)
- Q4 2023 (February 1, 2024)
 - [Report / Transcript](#)

Factors impacting YoY comparative figures

- **Order intake and net sales:** Read more about the order intake and net sales development on page 2 and 6-8 in the Q4 2023 report
- **Margins:** Read more about the margin development on page 3 and 6-8 in the Q4 2023 report
- **Sustainability:** Read more about the Sustainability development on page 5 in the Q3 2024 (sequentially) and Q4 2023 report (YoY)
- **Currency:** Getinge is net long USD versus SEK and EUR. I.e. in general, Getinge benefits from a stronger USD
- **Specific events and one offs:** Read more about any specific events and one offs on page 1 and 9 respectively in the notes on page 17-23 in the Q4 2023 report

Latest estimates

- [Consolidated analyst estimates \(Modular Finance\)](#)

Press releases during Q4 2024

- [Getinge news section](#)

Financial calendar

Interim report, Q4 Oct-Dec 2024	January 28, 2025
Interim report, Q1 Jan-Mar 2025	April 22, 2025
Annual General Meeting 2025	April 22, 2025
Interim report, Q2 Apr-Jun 2025	July 18, 2025

Contact information:

David Kördel, Head of Investor Relations

Phone: +46 (0)10 335 0077

Email: david.kordel@getinge.com

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.